Literature DB >> 9637359

Immunomodulatory properties of antiviral acyclic nucleotide analogues: cytokine stimulatory and nitric oxide costimulatory effects.

Z Zídek1, A Holý, D Franková.   

Abstract

Acyclic nucleotide analogues exhibit strong activity against a broad range of viruses, including HIV-1 and -2. We have investigated their effects on in vitro secretion of cytokines and production of nitric oxide (NO) by murine peritoneal macrophages, factors known to play a role in virus replication. Included in the study were the most prominent compounds of the series: 9-(2-phosphonomethoxyethyl)adenine, 9-(2-phosphonomethoxyethyl)-2,6-diaminopurine, the (R)- and (S)-enantiomers of 9-(2-phosphonomethoxypropyl) adenine [(R)- or (S)-PMPA], (R)- and (S)-enantiomers of 9-(2-phosphonomethoxypropyl)-2,6-diaminopurine [(R)- or (S)-PMPDAP], 9-(2-phosphonomethoxyethyl)guanine (PMEG), and (S)-enantiomer of 1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine [(S)-HPMPC]. PMEG, (R)-PMPA, and (S)-PMPA greatly enhanced the secretion of both tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), (R)-PMPDAP stimulated only TNF-alpha, other test compounds were ineffective. None of them influenced the secretion of IL-2 or interferon-gamma (IFN-gamma). Both TNF-alpha and IL-10 have been found to be major factors determining enhancing effects of PMEG, (R)-PMPA, and (S)-PMPA on production of NO generated by exogenous IFN-gamma. The study points to a possible implication of immunomodulatory properties in the antiviral effects of some acyclic nucleotide analogues. In addition, our data support the view that endogenous IL-10 can stimulate certain macrophage functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9637359     DOI: 10.1016/s0192-0561(97)00047-7

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; R Arnaout; L Li; T L Parks; D K Schneider; R F Kiser; V J Coalter; G Walsh; R J Imming; B Fisher; B M Flynn; N Bischofberger; M Piatak; V M Hirsch; M A Nowak; D Wodarz
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 2.  Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.

Authors:  Katherine A Lyseng-Williamson; Neil A Reynolds; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production.

Authors:  Z Zídek; D Franková; A Holý
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 4.  Tenofovir disoproxil fumarate.

Authors:  Therese Chapman; Jane McGavin; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice.

Authors:  Sanaa Botros; Samia William; Olfat Hammam; Zdenĕk Zídek; Antonín Holý
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.